Modality
siRNA
MOA
PCSK9i
Target
Menin
Pathway
Ferroptosis
WM
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
~Mar 2018
→ ~Jun 2019
NDA/BLA
~Sep 2019
→ ~Dec 2020
Approved
Mar 2021
ApprovedCurrent
NCT07169183
1,160 pts·WM
2021-03→TBD·Active
1,160 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Approved
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07169183 | Approved | WM | Active | 1160 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |